Iceland vs Türkiye: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Iceland
92.0%
in 2025
Türkiye
92.0%
in 2025
Iceland rank
56th
Türkiye rank
56th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Iceland
- Türkiye
How they compare
Iceland currently reports 92.0% against 92.0% in Türkiye, a difference of 0.0%.
Across all 18 years both countries report, Türkiye has been ahead every year.
Iceland ranks 56th and Türkiye ranks 56th of 194 countries.
Türkiye has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Iceland | Türkiye | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 48.5% | 48.5% | Türkiye |
| 2010s | 71.6% | 96.4% | 24.8% | Türkiye |
| 2020s | 91.0% | 94.5% | 3.5% | Türkiye |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Iceland or Türkiye?
- Iceland, at 92.0% against 92.0% in Türkiye as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Iceland and Türkiye?
- 0.0%, with Iceland ahead.
- How many years of comparable data are there for Iceland and Türkiye?
- 18 years are reported by both, from 2008 to 2025.
- How do Iceland and Türkiye rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Iceland ranks 56th and Türkiye ranks 56th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.